<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS156671</article-id><article-id pub-id-type="doi">10.1101/2022.11.03.515011</article-id><article-id pub-id-type="archive">PPR566708</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Evaluation of antibody kinetics and durability in health subjects vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Hangjie</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Hua</surname><given-names>Qianhui</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Nani</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xinpei</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Xijun</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Zhongbing</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Pengfei</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Huijun</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shenyu</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Linling</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Yuting</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Jianmin</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Huakun</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310057, China</aff><aff id="A2"><label>2</label>School of Medicine, Ningbo University, Ningbo, 315211, China</aff><aff id="A3"><label>3</label>Xihu District Center for Disease Control and Prevention, Hangzhou, 310007, China</aff><aff id="A4"><label>4</label>Shangyu District Center for Disease Control and Prevention, Shaoxing, 312399, China</aff><aff id="A5"><label>5</label>Kaihua District Center for Disease Control and Prevention, Quzhou, 324399, China</aff><aff id="A6"><label>6</label>Yuecheng District Center for Disease Control and Prevention, Shaoxing, 312099, China</aff><aff id="A7"><label>7</label>Department of Immunization Program, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China</aff><aff id="A8"><label>8</label>Longyou District Center for Disease Control and Prevention, Quzhou, 324499, China</aff><aff id="A9"><label>9</label>School of Public Health, Xiamen University, Xiamen, 361005, China</aff><author-notes><fn fn-type="equal" id="FN1"><label>†</label><p id="P1">Z.H.J. and H.Q.H. have contributed equally to this work and share first authorship</p></fn><corresp id="CR1">
<label>*</label>Corresponding authors: Huakun Lv (<email>hklv@cdc.zj.cn</email>) and Jianmin Jiang (<email>jmjiang@cdc.zj.cn</email>)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>06</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>04</day><month>11</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This work has been placed in the Public Domain.</license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P2">Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed.</p></sec><sec id="S2"><title>Methods</title><p id="P3">We enrolled 1067 volunteers who had been vaccinated with one or two doses of CoronaVac in Zhejiang Province, China. Another 90 healthy adults without previous vaccinations were recruited and vaccinated with three doses of CoronaVac, 28 days and 6 months apart. Serum samples were collected from multiple timepoints and analyzed for specific IgM/IgG and neutralizing antibodies (NAbs) for immunogenicity evaluation. Antibody responses to the Delta and Omicron variants were measured by pseudovirus-based neutralization tests.</p></sec><sec id="S3"><title>Results</title><p id="P4">Our results revealed that binding antibody IgM peaked 14−28 days after one dose of CoronaVac, while IgG and NAbs peaked approximately 1 month after the second dose then declined slightly over time. Antibody responses had waned by month 6 after vaccination and became undetectable in the majority of individuals at 12 months. Levels of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG and NAbs to pseudovirus, but not IgM. Homologous booster around 6 months after primary vaccination activated anamnestic immunity and raised NAbs 25.5-fold. The NAb inhibition rate subsequently rose to 36.0% for Delta (p=0.03) and 4.3% for Omicron (p=0.004), and the response rate for Omicron rose from 7.9% (7/89) to 17.8% (16/90).</p></sec><sec id="S4"><title>Conclusions</title><p id="P5">Two doses of CoronaVac vaccine resulted in limited protection over a short duration. The homologous booster slightly increased antibody responses to the Delta and Omicron variants; therefore, the optimization of booster procedures is vital.</p></sec><sec id="S5"><title>Funding</title><p id="P6">Key Research and Development Program of Zhejiang Province; Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission; Major Program of Zhejiang Municipal Natural Science Foundation.</p></sec></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>inactivated vaccine</kwd><kwd>dynamic changes</kwd><kwd>humoral immune response</kwd></kwd-group></article-meta></front><body><sec id="S6" sec-type="intro"><title>Introduction</title><p id="P7">The coronavirus disease 2019 (COVID-19), a global health emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to unprecedented global healthcare and economic burdens (<xref ref-type="bibr" rid="R11">Clark et al. 2020</xref>). COVID-19 vaccines are indispensable for mitigating this situation and containing the ongoing pandemic, especially in regions with high vaccination coverage, as shown by the decline in new and hospitalized COVID-19 cases since mass vaccination began (<xref ref-type="bibr" rid="R29">Rossman et al. 2021</xref>). Researchers from industrial and private firms are trialing different technologies, such as virus-, viral-vector-, nucleic-acid-, and protein-based vaccines (<xref ref-type="bibr" rid="R5">Callaway 2020</xref>).</p><p id="P8">Inactivated COVID-19 vaccines, such as CoronaVac and BBIBP-CorV, were proven to be generally safe and effective in adults in several clinical trials (<xref ref-type="bibr" rid="R34">Xia et al. 2022</xref>; <xref ref-type="bibr" rid="R33">Xia et al. 2020</xref>; <xref ref-type="bibr" rid="R32">Wu et al. 2021</xref>) and are widely used in China and abroad. Nevertheless, basic questions remain about the vaccine-induced longevity of immunity in the population and the rate of breakthrough infections (<xref ref-type="bibr" rid="R19">Kim et al. 2021</xref>). Several studies have gathered immunogenicity data on antibody kinetics after vaccination and showed that neutralizing titers induced by two doses of inactivated vaccine peaked in month 2 and declined to 33.89% by month 6 (<xref ref-type="bibr" rid="R10">Cheng et al. 2022</xref>). However, it is important to provide more data on the enhancement and attenuation of immunological protection after vaccination in real-world studies.</p><p id="P9">The SARS-CoV-2 variants that have been classified as variants of interest or variants of concern (VOC) by the World Health Organization (WHO) are responsible for multiple waves of infection (<xref ref-type="bibr" rid="R12">Dyson et al. 2021</xref>) and the increased concerns about the protection provided by current vaccines (<xref ref-type="bibr" rid="R26">Mlcochova et al. 2021</xref>; <xref ref-type="bibr" rid="R2">Altmann et al. 2021</xref>). The Omicron (B.1.1.529) variant recently identified in South Africa has spread globally (<xref ref-type="bibr" rid="R17">Karim and Karim 2021</xref>), raising concerns about the effectiveness of antibody therapies and vaccines to variants with multiple mutations (<xref ref-type="bibr" rid="R13">Flemming 2022</xref>; <xref ref-type="bibr" rid="R31">VanBlargan et al. 2022</xref>). A recent real-world study in Israel suggested that a third dose of BNT162b2 vaccine was highly effective in preventing infection, severe disease, hospitalization, and death (<xref ref-type="bibr" rid="R3">Barda et al. 2021</xref>). Booster vaccines reinstate waning immunological memory and expand the breadth of immune responses to SARS-CoV-2 variants (<xref ref-type="bibr" rid="R15">Goldberg et al. 2021</xref>; <xref ref-type="bibr" rid="R38">Zhu et al. 2021</xref>; <xref ref-type="bibr" rid="R9">Chen et al. 2022</xref>; <xref ref-type="bibr" rid="R6">Cao et al. 2021</xref>). Therefore, the provision of booster vaccinations for SARS-CoV-2 is recommended by the WHO and is being implemented for fully vaccinated recipients in China and other countries. However, data are needed on the protective immune responses elicited by the boosters against VOC in mass vaccination campaigns.</p><p id="P10">We explored the dynamic responses and durations of antibodies against SARS-CoV-2 in individuals within 1 year of being vaccinated with an inactivated COVID-19 vaccine and speculated on the protection provided based on the attenuation of neutralizing antibody levels. Furthermore, we evaluated the presence of neutralizing antibodies against Delta and Omicron in volunteers boosted with a third dose of inactivated vaccine.</p></sec><sec id="S7" sec-type="results"><title>Results</title><sec id="S8"><title>Study participant characteristics</title><p id="P11">We conducted a cross-sectional survey and recruited 1,067 volunteers who had no vaccination or were vaccinated with one or two doses of CoronaVac in October 2020 or later in this multicenter study. Participants ranged in age from 18 to 59 years, with a mean age of 40 (sd, 10) years, and there was a balanced distribution of males (43.3%) and females (56.7%). Samples were collected at eight timepoints, including Pre-V (n = 91), V1-14d (n = 125), and V1-28d (n = 91) after vaccination with the first dose and V2-1m (n=100), V2-3m (n=110), V2-6m (n=160), V2-9m (n=190), and V2-12m (n=200) after vaccination with the second dose (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Demographic data for the vaccine recipients are summarized in <xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="supplementary-material" rid="SD1">S1</xref>.</p><p id="P12">In the prospective cohort study, we recruited 90 healthy adults who met all inclusion criteria and no exclusion criteria, including 40 (44.4%) males and 50 (56.6%) females with a median age of 64 years (IQR, [39-70]), 33.3% of whom had a BMI of ≥24.0 kg/m<sup>2</sup>, and 33.3% had ≥1 underlying comorbidity (most commonly hypertension and diabetes) (<xref ref-type="table" rid="T2">Table 2</xref>). The participants were administered a standard dose of the CoronaVac vaccine on days 0 and 28 and a booster dose after month 7. Blood samples were collected at study visit 0 (Pre-V) before vaccination; visit 1 (V2-1m), visit 2 (V2-3m), and visit 3 (V2-6m) after vaccination with the second dose; and visit 4 (V3-1m) after the third dose (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p></sec><sec id="S9"><title>Dynamics of antibody responses to primary vaccination</title><p id="P13">To explore the dynamic changes in humoral immune responses to the inactivated COVID-19 vaccine, we first evaluated the recipients’ anti-S and anti-N IgM and IgG development at different timepoints (<xref ref-type="fig" rid="F2">Figure 2A</xref>). The titer of S- and N-IgM on day 0 increased to 5.1 ± 1.0 AU/ml on day 28 after the first dose, though the positive rate was 57.6%. The positive rates of S- and N-IgM reached a peak of 75.8% (5.1 ± 0.9 AU/ml) approximately 28 days after the first dose, while the positive rates of S- and N-IgG reached 97.0% (79.7 ± 5.7 AU/ml) approximately 28 days after the second dose. The titer of S- and N-IgM rapidly declined to 1.4 ± 0.2 AU/ml, which is close to the critical value, 28 days after the second dose, while S- and N-IgG declined to 10.5 ± 0.9 AU/ml during month 6 after the second dose. A small percentage of the population still had anti-S and anti-N IgG antibodies, with positive rates of 22.1% and 13.5%, respectively, during months 9 and 12 after the second dose (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p id="P14">S protein RBD binding to the angiotensin converting enzyme 2 (ACE2) receptor is a critical initial step in the entry of SARS-CoV-2 into target cells (<xref ref-type="bibr" rid="R39">Zuo et al. 2022</xref>). We detected the anti-RBD IgM and IgG levels in the serum samples at several timepoints after the second dose (<xref ref-type="fig" rid="F2">Figure 2B</xref>). The results were similar to those for anti-S and anti-N antibodies, showing peak levels of RBD-IgM (1.8 ± 0.4 AU/ml) and RBD-IgG (18.0 ± 1.6 AU/ml) 1 month after the second dose, after which, the levels of both gradually waned. Furthermore, analysis showed a good correlation between IgM or IgG and anti-S/N and anti-RBD antibodies (R<sup>2</sup> = 0.7364, P &lt; 0.001; R<sup>2</sup> = 0.7170, P &lt; 0.001, <xref ref-type="fig" rid="F2">Figure 2C</xref>).</p><p id="P15">Participants were tested with a live virus-based and pseudovirus-based neutralization assay. As depicted in <xref ref-type="fig" rid="F3">Figure 3A</xref>, samples were negative for NAbs at the prevaccine baseline, and 87.0% of recipients had a NAb titer greater than 1:4 after the administration of the second dose, along with a GMT of 20.2 (95% CI: 16.3−24.9). Despite the decline observed in month 1, the values did not differ significantly between month 1 and month 3 (P = 0.052). However, 12 months after immunization, 35.5% of the population were Nab-positive, with a GMT of 4.1 (95% CI: 3.7−4.5). Additionally, the NAb inhibition rate for the pseudovirus was significantly elevated (76.2% ± 1.6, P &lt; 0.001) at 1 month after the second dose and decreased slightly thereafter (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Correlation analysis showed no correlation between the anti-S/anti-N/RBD IgM and NAb titers (R<sup>2</sup> = 0.0139, P = 0.243; R<sup>2</sup> = 0.010, P = 0.322), whereas the levels of anti-S, anti-N, and RBD IgGs showed poor correlations with the NAb titer (R<sup>2</sup> = 0.0871, P = 0.003; R<sup>2</sup> = 0.1209, P &lt; 0.001) and moderate correlations with the NAb inhibition rate (R<sup>2</sup> = 0.5393, P &lt; 0.001; R<sup>2</sup> = 0.4707, P &lt; 0.001).</p></sec><sec id="S10"><title>Antibody responses before and after booster immunization</title><p id="P16">With the dampening of antibody responses to the CoronaVac vaccine, we gave the cohort of 90 individuals booster immunizations up to 6 months after the second dose, and the antibody-titer-level distributions are shown in the violin plot in <xref ref-type="fig" rid="F4">Figure 4</xref>. At month 1 after the second dose, the positive rates of anti-S/anti-N and anti-RBD IgGs were 96.7% and 100.0% and reached peak levels of 67.4 ± 5.0 AU/ml and 9.4 ± 0.8 AU/ml, respectively, after which point, they slowly diminished over time to 9.4 ± 1.6 AU/ml and 2.8 ± 0.2 AU/ml, respectively, in month 6. Injection of the booster dose stimulated these levels back to 131.3 ± 8.6 AU/ml and 21.7 ± 1.8 AU/ml at month 1 post-booster, 14.0- and 7.8-fold increases from the lowest point, respectively (<xref ref-type="fig" rid="F4">Figure 4A</xref> and <xref ref-type="fig" rid="F4">4B</xref>).</p><p id="P17">After the two basic injections and the third booster dose, a similar increasing trend was observed in the two neutralization test results (<xref ref-type="fig" rid="F4">Figure 4C and 4D</xref>). The GMT of the NAb titer peaked at 29.4 (95% CI: 23.5−24.2) and dropped to 6.6 (95% CI: 5.4−8.0) at month 6, which was a 4.5-fold attenuation of the peak value, with the total positive rate dropping from 98.9% to 57.8%. After the booster dose, the GMT increased to 168.2 (95% CI: 139.7−202.6), i.e., 25.5-fold higher, at month 6, which was 5.7-fold higher than the first peak. This showed that the NAb inhibition rate for the pseudovirus peaked at 72.7% ± 1.6% before gradually decreasing to 21.4% ± 1.7% in month 6 but increased to 84.3% ± 1.7% after the booster.</p><p id="P18">The levels of antibodies grouped by age (i.e., 18−44 y.o., 45−64 y.o., and ≥65 y.o.), sex, BMI, and chronic conditions at each monitoring point are presented in <xref ref-type="table" rid="T3">Tables 3</xref> and <xref ref-type="supplementary-material" rid="SD1">S3</xref>. The Nab titer showed a statistically significant difference among age groups during months 1−6 after the basic vaccination, but there was no significant difference (p = 0.369) after the booster dose. Females exhibited a higher NAb titer than males [199.3 (95% CI: 159.2−249.5) vs 136.1 (95% CI: 99.9− 185.4), p = 0.039] after the booster vaccination. However, there were no statistically significant differences in antibody titer levels between the different BMI or chronic conditions groups.</p></sec><sec id="S11"><title>Antibody responses to Delta and Omicron variants</title><p id="P19">Mutations in the RBD may lead to a reduction in the antibody neutralization susceptibility of VOC (<xref ref-type="bibr" rid="R23">Liu et al. 2021</xref>). We furthermore measured the levels of neutralizing antibodies against the Delta (B.I.617.2) and Omicron (B.1.1.529) variants from serum samples in month 1 after the basic and booster immunizations (<xref ref-type="fig" rid="F5">Figure 5</xref>). Of note, in individuals vaccinated with two doses of the inactivated vaccine, the NAb inhibition rate for the pseudovirus against the Delta variant and, in particular, the Omicron variant were much lower compared with that against the Wuhan strain (28.4% vs 72.4%, 0.5% vs 72.4%, p ≤ 0.001). However, the prime-boost vaccination gave rise to a slight increase in neutralizing activity against the variants. The inhibition rate subsequently rose to 36.0% for Delta (p = 0.03) and 4.3% (p = 0.004) for Omicron after one booster dose of inactivated vaccine. The response rate for Omicron rose from 7.9% (7/89) to 17.8% (16/90).</p></sec></sec><sec id="S12" sec-type="discussion"><title>Discussion</title><p id="P20">Inactivated vaccines have been used on an unprecedented scale worldwide, mainly to reduce the COVID-19 severity and hospitalization rate and number of related deaths (<xref ref-type="bibr" rid="R16">Jara et al. 2021</xref>; <xref ref-type="bibr" rid="R25">Medeiros-Ribeiro et al. 2021</xref>). However, there has been no correlation between immunization and protection or duration of protection demonstrated for inactivated COVID-19 vaccines. Our study of post-vaccination antibody kinetics showed that IgM levels peaked 14−28 days after one dose of CoronaVac, after which point, they declined rapidly. Two doses of the completely inactivated vaccine induced high levels of IgG and neutralizing antibodies, which peaked approximately 1 month after vaccination and declined slightly over time. The vaccine-induced immunity had notably waned to lower levels 6 months later and became undetectable in the majority of individuals 12 months later.</p><p id="P21">Previous studies have shown that antibody responses usually decline over time after an initial COVID-19 vaccination. Following vaccination with the Pfizer BNT162b2 vaccine, humoral responses were substantially decreased after 6 months among healthcare workers in Israel of 65 years of age or older, especially men (<xref ref-type="bibr" rid="R21">Levin et al. 2021</xref>). In addition, a significant trend of declining S-antibody levels was observed following AstraZeneca ChAdOx1 and BNT162b2 administration, with levels reducing by about 5-fold and 2-fold 21−41 days and 70 days or more after the second dose, respectively (<xref ref-type="bibr" rid="R30">Shrotri et al. 2021</xref>). It was reported that the immunity provided by inactivated COVID-19 vaccines, such as CoronaVac and Sinopharm/BBIBP, endured for 6 months, with a NAb GMT of 6.8 (95%CI: 5.2−8.8) and 2.31 (95%CI: 2.1−2.6) in month 6 after the two doses and seropositivity of 35% and 61%, respectively (<xref ref-type="bibr" rid="R10">Cheng et al. 2022</xref>; <xref ref-type="bibr" rid="R35">Zeng et al. 2022</xref>). In our study, the seropositivity and GMT of CoronaVac remained at 57.8% and 6.6 (95% CI: 5.4−8.0), respectively, for 6 months after the basic vaccination, which is comparable to prior reported data on inactivated vaccines (<xref ref-type="bibr" rid="R10">Cheng et al. 2022</xref>), although the immunogenicity was lower than that of other types of COVID-19 vaccines. However, the neutralization antibody response levels of different vaccines are difficult to directly compare because of a lack of standardized laboratory methods for SARS-CoV-2 neutralization and differences in experimental conditions(<xref ref-type="bibr" rid="R8">Chen et al. 2021</xref>).</p><p id="P22">We also assessed the dynamics of antibody levels in a small prospective longitudinal cohort 6 months following two vaccination doses and found they were consistent with the above findings. Importantly, a booster injection around 6 months after the primary series of vaccinations activated the anamnestic immunity and raised immune components (such as NAbs) to higher levels. Additionally, several factors, such as age group, sex, obesity, and chronic conditions affecting neutralizing antibody levels, were analyzed. We found that initial and booster-vaccine-elicited neutralizing antibody titers were negatively associated with age, resulting in a diminished ability to rescue in vitro cells from SARS-CoV-2 infection in vitro, similar to the findings described in many other reports (<xref ref-type="bibr" rid="R35">Zeng et al. 2022</xref>; <xref ref-type="bibr" rid="R4">Bates et al. 2021</xref>). There is evidence of vaccination-induced protection against severe COVID-19 in people with excess weight or obesity of a similar magnitude to that in people of a healthy weight (<xref ref-type="bibr" rid="R28">Piernas et al. 2022</xref>), and we found the COVID-19 neutralizing antibody titer was not associated with bodyweight. The comorbidities had no significant effect on NAb levels in our study, which agrees with another other study that demonstrated that inactivated COVID-19 vaccines had good immunogenicity and safety in older patients with hypertension and/or diabetes mellitus (<xref ref-type="bibr" rid="R37">Zhang et al. 2022</xref>). NAbs levels following the CoronaVac booster vaccine was found to have an association with sex, though the BNT162b2 mRNA vaccine was reported to induce higher antibody levels in women than men (<xref ref-type="bibr" rid="R24">Lustig et al. 2021</xref>).</p><p id="P23">The live SARS-CoV2 neutralizing antibody test has been used as a gold standard for evaluating vaccine immunogenicity in clinical trials and has shown correlations with protection from COVID-19 for real-world vaccinations (<xref ref-type="bibr" rid="R14">Gilbert et al. 2022</xref>; <xref ref-type="bibr" rid="R18">Khoury et al. 2021</xref>). However, the operation of this live virus detection method should be restricted to BSL-3 laboratory conditions, and there are potential biosafety risks and higher economic costs involved. In our study, we compared different methods of detecting the vaccine immunogenicity of serum samples with binding antibodies (IgM/IgG) and live and pseudovirus-based virus neutralizing antibodies. We found the correlations between both IgM and IgG S/N and RBD antibodies to be very strong. Moreover, the titers of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG or NAbs to pseudovirus; however, NAbs to live SARS-CoV-2 did not correlate well with anti-SARS-CoV-2 IgM levels. This might be attributable to the rapid attenuation of IgM at the incipient stage and its further decrease over time and the contribution of IgG to increases in neutralizing antibody and IgM. Therefore, IgG S- and RBD-binding antibody and pseudovirus-based neutralizing antibody detection methods can be applied to partly substitute for serological tests rather than live virus-neutralizing tests.</p><p id="P24">The Delta variant has eight mutations of the S protein, two of which are within the RBD, while there are 30 mutations in Omicron variant B.1, with half of the mutations within the RBD (<xref ref-type="bibr" rid="R20">Kumar et al. 2022</xref>). Our results revealed the capability of the SARS-CoV-2 Delta and Omicron variants to escape the antibodies induced by the inactivated vaccine after both primary and booster doses. While vaccinated sera shows decreased neutralizing activity against the Delta variant, Omicron evades the antibodies elicited by the inactivated vaccine efficiently, with a steep reduction in neutralization. In the current stages of the pandemic, with emerging Omicron variants (BA.4/5), the optimization of booster procedures, such as homologous vaccination, is very important (<xref ref-type="bibr" rid="R1">Accorsi et al. 2022</xref>).</p><p id="P25">However, there were some limitations to this investigation. First, the sample size in this study was based on practical considerations rather than statistical power calculations, and the distribution of age and sex were not very well balanced in the study. Second, vaccine efficacy was not calculated, as we did not compare the NAb titers generated by vaccination with those of convalescent COVID-19 patients or a serum standard panel in parallel. Third, we assessed only serum antibody responses, and further evaluations focusing on memory and cellular immunity are needed. Forth, we only detected the titers of NAbs to Delta and Omicron with pseudovirus-based neutralizing test.</p><p id="P26">In conclusion, our study suggests that vaccination against SARS-CoV-2 with two doses of CoronaVac can trigger humoral responses in the majority of vaccination recipients aged 18 to 59 years. Although binding and neutralizing antibodies were still detectable at 12 months post-vaccine, serum antibody levels tended to decrease over time, and Delta and Omicron variants may be able to more efficiently evade the antibodies induced by the inactivated vaccine with time. A booster dose can reverse the decrease in antibody levels and heighten the cross immune response to variants. This implies that the protective capability of a primary vaccination series is enhanced following booster doses and optimization of the booster procedure.</p></sec><sec id="S13" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S14"><title>Study design and participants</title><p id="P27">The cross-sectional investigation was conducted in five counties of Zhejiang Province, mainland China (Xihu, Yuecheng, Shangyu, Kaihua, and Longyou Districts), after nationwide COVID-19 vaccinations from May to October 2021. Potential participants aged 18−59 years who had had no prior vaccinations or were vaccinated with one or two doses of CoronaVac (Sinovac Life Sciences, Beijing, China) were recruited from the community. Individuals with a history of infection with SARS-CoV-2 or the use of blood products or immunosuppressive drugs were excluded. We randomly enrolled 1067 volunteers, including those on day 0 (Pre-V, no vaccination), day 14 ± 2 (V1-14d), and day 28 ± 3 (V1-28d) after the first vaccine dose, and day 30 ± 3 (V2-1m), day 90 ± 7 (V2-3m), day 180 ± 14 (V2−6m), day 270 ± 14 (V2-9m), and day 365 ± 30 (V2-12m) after the second dose and collected their venous blood samples (3−5 ml) to detect serum antibody levels (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). This was not a longitudinal survey, as different subjects were enrolled at each point in time. We employed a questionnaire survey at blood drawing visits to gather demographic information.</p><p id="P28">In the prospective cohort study, we recruited 90 healthy adults aged 18−80 years from Jiaxing city, Zhejiang, in June 2021. The main exclusion criteria included previous or later SARS-CoV-2 infection; allergy to any ingredient included in the vaccine; those who had received any blood products or any research medicines or vaccines in the past month; those who had uncontrolled epilepsy or other serious neurological diseases, acute febrile disease, acute onset of chronic diseases, or uncontrolled severe chronic diseases; and those who were unable to comply with the study schedule. Subjects were administered 4 μg/0.5 mL of CoronaVac following a 3-shot vaccine schedule 28 days and 6 months apart. Following that, venous blood (3−5 ml) was collected from recipients at five time points: day 0 (Pre-V, before vaccination), day 30 ± 3 (V2-1m), day 90 ± 7 (V2-3m), and day 180 ± 14 (V2-6m) after the second dose, and day 30 ± 3 (V3-1m) after the third dose (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p></sec><sec id="S15"><title>SARS-CoV-2-specific IgG and IgM assay</title><p id="P29">The commercial detection kit iFlash-2019-nCoV NAb assay (Shenzhen YHLO Biotech Co. Ltd., Shenzhen, China) was employed to measure the levels of IgG and IgM against SARS-CoV-2 spike glycoprotein (S) and nucleocapsid protein (N) by chemiluminescence immunoassay. Briefly, serum samples were allowed to form a complex with SARS-CoV-2 S- and N-protein antigen-coated paramagnetic microparticles, then an acridinium-ester-labeled ACE2 conjugate was added to competitively combine with the particles, forming another reaction mixture. The analyzer converted relative light units (RLUs) into an antibody titer (AU/mL) through a two-point calibration curve. An inverse relationship existed between the amount of SARS-CoV-2 NAb in the sample and the RLUs detected by the iFlash optical system. According to the manufacturer, titers of ≥10.0 AU/mL and ≥1.0 AU/mL are considered positive (or reactive) for IgG and IgM, respectively. IgG and IgM against SARS-CoV-2 receptor binding domain (RBD) were detected using a commercial ELISA kit (Bioscience Biotech Co. Ltd., Chongqing, China). The positive cutoff values for RBD-specific IgG and IgM antibodies were defined as titers of ≥1.0 AU/mL. All tests were performed according to the manufacturer’s protocols (<xref ref-type="bibr" rid="R7">Chan et al. 2021</xref>; <xref ref-type="bibr" rid="R22">Li et al. 2021</xref>).</p></sec><sec id="S16"><title>Live virus neutralization antibody assays</title><p id="P30">The levels of neutralizing antibodies to live SARS-CoV-2 were assessed by the reduction in the cytopathic effect (CPE) in Vero cells with infectious SARS-CoV-2 strain 19nCoVCDC-Tan-HB01 (HB01) in a BSL-3 laboratory(<xref ref-type="bibr" rid="R36">Zhang et al. 2021</xref>). Briefly, serum samples were heat-inactivated for 30 min at 56°C and successively diluted from 1:4 to the required concentration in a 2-fold series. An equal volume of challenge solution containing 100 TCID50 virus was added. After neutralization in a 37°C incubator for 2 h, a 1.5−2.5 × 10<sup>5</sup>/ml cell suspension was added to the wells. The CPE on VeroE6 cells was analyzed at 4-days post-infection. Neutralization titers (NT50) were expressed as the reciprocal of the highest dilution protecting 50% of the cells from virus challenge. NAb titers above 1:4 was defined as positive.</p></sec><sec id="S17"><title>Pseudovirus-based neutralization test</title><p id="P31">Serum samples were also quantified for their content of SARS-CoV-2-neutralizing antibodies to wildtype (Wuhan), Delta (B.I.617.2), and Omicron (B.1.1.529) using the pseudovirus-based virus neutralization test (<xref ref-type="bibr" rid="R27">Nie et al. 2020</xref>). Briefly, serum samples and a positive or negative reference sample were each diluted 50 times with phosphate-buffered saline combined with 50 μl of pseudovirus diluent per well in a 96-well plate. The mixed sample/pseudovirus was incubated at 37°C and 5% CO<sub>2</sub> for 1 h. A 2 × 10<sup>5</sup>/ml BHK-21-ACE2 cell suspension was added to each well of the plate containing the sample/pseudovirus mixture, then the plate was incubated in a 37°C and 5% CO<sub>2</sub> cell incubator for 48 h. Finally, the number of green-fluorescence-protein-positive cells per well was read with a porous plate imager (Tecan, Shanghai, SparkCyto). The positive and negative cut-off values for SARS-CoV-2 NAb detection were interpreted based on the inhibition rate (≥50%). The results were determined by comparing the inhibition rate using the following calculation: (1 − fluorescence value of each well/average virus control value) × 100%. The conversion of NAb inhibition rate to serum titer is shown in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>.</p></sec><sec id="S18"><title>Statistical analysis</title><p id="P32">Sex, age, BMI, and other clinical characteristics were collected for each vaccination recipient. We used the mean ± standard deviation (sd), medians, and interquartile ranges (IQR) for continuous variables, and numbers (percentages) for categorical variables. Specific binding antibodies against SARS-CoV-2 (IgG, IgM) and inhibition rates of SARS-CoV-2-neutralizing antibodies are presented as mean ± standard error (SEM). Neutralizing antibodies are presented as geometric mean titers (GMT), and their 95% confidence interval (CI) was calculated with Student’s t distribution on log-transformed data and then back-transformed. Comparisons of titer-level differences between the two groups were performed using the paired Student’s t-test. One-way analysis of variance (one-way ANOVA) was used to analyze the differences between the mean values at different timepoints. Correlations between NAb titers, inhibition rates, and IgG/IgM levels were evaluated by Pearson’s correlation coefficient. Statistical tests were two-sided, and we considered p-values of less than 0.05 as statistically significant. All statistical analyses were conducted in SPSS 18.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 9 (San Diego CA, USA).</p></sec><sec id="S19"><title>Compliance and ethics</title><p id="P33">The author(s) declare that they have no conflict of interest. For studies involving human, the authors also state that they conformed with the Helsinki Declaration of 1975 (as revised in 2008) concerning Human and Animal Rights, and that they followed out the policy concerning Informed Consent as shown on Springer.com. The study protocol and informed consent form were approved by the Medical Ethics Committee of The Zhejiang Center for Disease Control and Prevention (2021-044-01). Written informed consent was obtained from all study participants.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS156671-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d4aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S20"><title>Acknowledgements</title><p>We would like to thank the staff from the local CDCs and the local designated hospitals for their help with the field survey. We also sincerely thank professor Xiaofeng Qin in Suzhou Institute of Systematic Medicine for assisting us to detect the pseudovirus-based neutralization antibody. This work was supported by the Key Research and Development Program of Zhejiang Province (2021C03200); the Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission (WKJ-ZJ-2221); the Major Program of Zhejiang Municipal Natural Science Foundation (LD22H190001).</p></ack><sec id="S21" sec-type="data-availability"><title>Data availability statements</title><p id="P34">All data generated or analysed during this study are included in this published article and its supplementary information files, or are available from the corresponding author on reasonable request.</p></sec><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Accorsi</surname><given-names>EK</given-names></name><name><surname>Britton</surname><given-names>A</given-names></name><name><surname>Shang</surname><given-names>N</given-names></name><name><surname>Fleming-Dutra</surname><given-names>KE</given-names></name><name><surname>Link-Gelles</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>ZR</given-names></name><name><surname>Derado</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Schrag</surname><given-names>SJ</given-names></name><name><surname>Verani</surname><given-names>JR</given-names></name></person-group><article-title>Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><fpage>2433</fpage><lpage>35</lpage></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altmann</surname><given-names>DM</given-names></name><name><surname>Boyton</surname><given-names>RJ</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name></person-group><article-title>Immunity to SARS-CoV-2 variants of concern</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>1103</fpage><lpage>04</lpage></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barda</surname><given-names>N</given-names></name><name><surname>Dagan</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Hernán</surname><given-names>MA</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>Reis</surname><given-names>BY</given-names></name><name><surname>Balicer</surname><given-names>RD</given-names></name></person-group><article-title>Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2093</fpage><lpage>100</lpage></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>TA</given-names></name><name><surname>Leier</surname><given-names>HC</given-names></name><name><surname>Lyski</surname><given-names>ZL</given-names></name><name><surname>Goodman</surname><given-names>JR</given-names></name><name><surname>Curlin</surname><given-names>ME</given-names></name><name><surname>Messer</surname><given-names>WB</given-names></name><name><surname>Tafesse</surname><given-names>FG</given-names></name></person-group><article-title>Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>868</fpage><lpage>9</lpage></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E</given-names></name></person-group><article-title>The race for coronavirus vaccines: a graphical guide</article-title><source>Nature</source><year>2020</year><volume>580</volume><fpage>576</fpage><lpage>77</lpage></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yisimayi</surname><given-names>A</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>T</given-names></name><name><surname>An</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines</article-title><source>Cell Res</source><year>2021</year><volume>31</volume><fpage>732</fpage><lpage>41</lpage></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Leung</surname><given-names>KY</given-names></name><name><surname>Zhang</surname><given-names>RR</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name></person-group><article-title>Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples</article-title><source>Diagnostics (Basel)</source><year>2021</year><volume>11</volume><fpage>1757</fpage></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Azman</surname><given-names>AS</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination</article-title><source>medRxiv</source><year>2021</year></element-citation></ref><ref id="R9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><etal/></person-group><article-title>The third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants</article-title><source>Emerg Microbes Infect</source><year>2022</year><volume>11</volume><fpage>1524</fpage><lpage>1536</lpage></element-citation></ref><ref id="R10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>ZJ</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhan</surname><given-names>Z</given-names></name><name><surname>Gan</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization</article-title><source>Allergy</source><year>2022</year><volume>77</volume><fpage>2404</fpage><lpage>2414</lpage></element-citation></ref><ref id="R11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name><name><surname>Warren-Gash</surname><given-names>C</given-names></name><name><surname>Guthrie</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>HHX</given-names></name><name><surname>Mercer</surname><given-names>SW</given-names></name><name><surname>Sanderson</surname><given-names>C</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Troeger</surname><given-names>C</given-names></name><name><surname>Ong</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study</article-title><source>Lancet Glob Health</source><year>2020</year><volume>8</volume><fpage>e1003</fpage><lpage>e17</lpage></element-citation></ref><ref id="R12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyson</surname><given-names>L</given-names></name><name><surname>Hill</surname><given-names>EM</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Curran-Sebastian</surname><given-names>J</given-names></name><name><surname>Tildesley</surname><given-names>MJ</given-names></name><name><surname>Lythgoe</surname><given-names>KA</given-names></name><name><surname>House</surname><given-names>T</given-names></name><name><surname>Pellis</surname><given-names>L</given-names></name><name><surname>Keeling</surname><given-names>MJ</given-names></name></person-group><article-title>Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><elocation-id>5730</elocation-id></element-citation></ref><ref id="R13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname><given-names>A</given-names></name></person-group><article-title>Omicron, the great escape artist</article-title><source>Nat Rev Immunol</source><year>2022</year><volume>22</volume><fpage>75</fpage></element-citation></ref><ref id="R14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>PB</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>McDermott</surname><given-names>AB</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Benkeser</surname><given-names>D</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Houchens</surname><given-names>CR</given-names></name><name><surname>Martins</surname><given-names>K</given-names></name><name><surname>Jayashankar</surname><given-names>L</given-names></name><etal/></person-group><article-title>Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>43</fpage><lpage>50</lpage></element-citation></ref><ref id="R15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>Y</given-names></name><name><surname>Mandel</surname><given-names>M</given-names></name><name><surname>Bar-On</surname><given-names>YM</given-names></name><name><surname>Bodenheimer</surname><given-names>O</given-names></name><name><surname>Freedman</surname><given-names>L</given-names></name><name><surname>Haas</surname><given-names>EJ</given-names></name><name><surname>Milo</surname><given-names>R</given-names></name><name><surname>Alroy-Preis</surname><given-names>S</given-names></name><name><surname>Ash</surname><given-names>N</given-names></name><name><surname>Huppert</surname><given-names>A</given-names></name></person-group><article-title>Waning Immunity after the BNT162b2 Vaccine in Israel</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><elocation-id>e85</elocation-id></element-citation></ref><ref id="R16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jara</surname><given-names>A</given-names></name><name><surname>Undurraga</surname><given-names>EA</given-names></name><name><surname>González</surname><given-names>C</given-names></name><name><surname>Paredes</surname><given-names>F</given-names></name><name><surname>Fontecilla</surname><given-names>T</given-names></name><name><surname>Jara</surname><given-names>G</given-names></name><name><surname>Pizarro</surname><given-names>A</given-names></name><name><surname>Acevedo</surname><given-names>J</given-names></name><name><surname>Leo</surname><given-names>K</given-names></name><name><surname>Leon</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>875</fpage><lpage>84</lpage></element-citation></ref><ref id="R17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>SSA</given-names></name><name><surname>Karim</surname><given-names>QA</given-names></name></person-group><article-title>Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2126</fpage><lpage>28</lpage></element-citation></ref><ref id="R18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>DS</given-names></name><name><surname>Cromer</surname><given-names>D</given-names></name><name><surname>Reynaldi</surname><given-names>A</given-names></name><name><surname>Schlub</surname><given-names>TE</given-names></name><name><surname>Wheatley</surname><given-names>AK</given-names></name><name><surname>Juno</surname><given-names>JA</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Triccas</surname><given-names>JA</given-names></name><name><surname>Davenport</surname><given-names>MP</given-names></name></person-group><article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>1205</fpage><lpage>11</lpage></element-citation></ref><ref id="R19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Marks</surname><given-names>F</given-names></name><name><surname>Clemens</surname><given-names>JD</given-names></name></person-group><article-title>Looking beyond COVID-19 vaccine phase 3 trials</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>205</fpage><lpage>11</lpage></element-citation></ref><ref id="R20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Thambiraja</surname><given-names>TS</given-names></name><name><surname>Karuppanan</surname><given-names>K</given-names></name><name><surname>Subramaniam</surname><given-names>G</given-names></name></person-group><article-title>Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein</article-title><source>J Med Virol</source><year>2022</year><volume>94</volume><fpage>1641</fpage><lpage>49</lpage></element-citation></ref><ref id="R21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>EG</given-names></name><name><surname>Lustig</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Fluss</surname><given-names>R</given-names></name><name><surname>Indenbaum</surname><given-names>V</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><name><surname>Doolman</surname><given-names>R</given-names></name><name><surname>Asraf</surname><given-names>K</given-names></name><name><surname>Mendelson</surname><given-names>E</given-names></name><name><surname>Ziv</surname><given-names>A</given-names></name><etal/></person-group><article-title>Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><elocation-id>e84</elocation-id></element-citation></ref><ref id="R22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals</article-title><source>Hum Vaccin Immunother</source><year>2021</year><volume>17</volume><fpage>3310</fpage><lpage>13</lpage></element-citation></ref><ref id="R23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Van Blargan</surname><given-names>LA</given-names></name><name><surname>Bloyet</surname><given-names>LM</given-names></name><name><surname>Rothlauf</surname><given-names>PW</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Stumpf</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Errico</surname><given-names>JM</given-names></name><name><surname>Theel</surname><given-names>ES</given-names></name><name><surname>Liebeskind</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>477</fpage><lpage>88</lpage><elocation-id>e4</elocation-id></element-citation></ref><ref id="R24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lustig</surname><given-names>Y</given-names></name><name><surname>Sapir</surname><given-names>E</given-names></name><name><surname>Regev-Yochay</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Fluss</surname><given-names>R</given-names></name><name><surname>Olmer</surname><given-names>L</given-names></name><name><surname>Indenbaum</surname><given-names>V</given-names></name><name><surname>Mandelboim</surname><given-names>M</given-names></name><name><surname>Doolman</surname><given-names>R</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><etal/></person-group><article-title>BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers</article-title><source>Lancet Respir Med</source><year>2021</year><volume>9</volume><fpage>999</fpage><lpage>1009</lpage></element-citation></ref><ref id="R25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros-Ribeiro</surname><given-names>AC</given-names></name><name><surname>Aikawa</surname><given-names>NE</given-names></name><name><surname>Saad</surname><given-names>CGS</given-names></name><name><surname>Yuki</surname><given-names>EFN</given-names></name><name><surname>Pedrosa</surname><given-names>T</given-names></name><name><surname>Fusco</surname><given-names>SRG</given-names></name><name><surname>Rojo</surname><given-names>PT</given-names></name><name><surname>Pereira</surname><given-names>RMR</given-names></name><name><surname>Shinjo</surname><given-names>SK</given-names></name><name><surname>Andrade</surname><given-names>DCO</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>1744</fpage><lpage>51</lpage></element-citation></ref><ref id="R26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mlcochova</surname><given-names>P</given-names></name><name><surname>Kemp</surname><given-names>SA</given-names></name><name><surname>Dhar</surname><given-names>MS</given-names></name><name><surname>Papa</surname><given-names>G</given-names></name><name><surname>Meng</surname><given-names>B</given-names></name><name><surname>Ferreira</surname><given-names>I</given-names></name><name><surname>Datir</surname><given-names>R</given-names></name><name><surname>Collier</surname><given-names>DA</given-names></name><name><surname>Albecka</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion</article-title><source>Nature</source><year>2021</year><volume>599</volume><fpage>114</fpage><lpage>19</lpage></element-citation></ref><ref id="R27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Nie</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><fpage>680</fpage><lpage>86</lpage></element-citation></ref><ref id="R28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piernas</surname><given-names>C</given-names></name><name><surname>Patone</surname><given-names>M</given-names></name><name><surname>Astbury</surname><given-names>NM</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Dixon</surname><given-names>S</given-names></name><name><surname>Coupland</surname><given-names>C</given-names></name><name><surname>Aveyard</surname><given-names>P</given-names></name><etal/></person-group><article-title>Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study</article-title><source>Lancet Diabetes Endocrinol</source><year>2022</year><volume>10</volume><fpage>571</fpage><lpage>80</lpage></element-citation></ref><ref id="R29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossman</surname><given-names>H</given-names></name><name><surname>Shilo</surname><given-names>S</given-names></name><name><surname>Meir</surname><given-names>T</given-names></name><name><surname>Gorfine</surname><given-names>M</given-names></name><name><surname>Shalit</surname><given-names>U</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name></person-group><article-title>COVID-19 dynamics after a national immunization program in Israel</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>1055</fpage><lpage>61</lpage></element-citation></ref><ref id="R30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrotri</surname><given-names>M</given-names></name><name><surname>Navaratnam</surname><given-names>AMD</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Byrne</surname><given-names>T</given-names></name><name><surname>Geismar</surname><given-names>C</given-names></name><name><surname>Fragaszy</surname><given-names>E</given-names></name><name><surname>Beale</surname><given-names>S</given-names></name><name><surname>Fong</surname><given-names>WLE</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Kovar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Spike-antibody waning after second dose of BNT162b2 or ChAdOx1</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>385</fpage><lpage>87</lpage></element-citation></ref><ref id="R31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>VanBlargan</surname><given-names>LA</given-names></name><name><surname>Errico</surname><given-names>JM</given-names></name><name><surname>Halfmann</surname><given-names>PJ</given-names></name><name><surname>Zost</surname><given-names>SJ</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Purcell</surname><given-names>LA</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><article-title>An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>490</fpage><lpage>95</lpage></element-citation></ref><ref id="R32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><fpage>803</fpage><lpage>12</lpage></element-citation></ref><ref id="R33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials</article-title><source>JAMA</source><year>2020</year><volume>324</volume><fpage>951</fpage><lpage>60</lpage></element-citation></ref><ref id="R34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Lou</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><fpage>196</fpage><lpage>208</lpage></element-citation></ref><ref id="R35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><fpage>483</fpage><lpage>95</lpage></element-citation></ref><ref id="R36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Ke</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects</article-title><source>Front Cell Infect Microbiol</source><year>2021</year><volume>11</volume><elocation-id>791660</elocation-id></element-citation></ref><ref id="R37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus</article-title><source>Vaccines (Basel)</source><year>2022</year><volume>10</volume><fpage>1020</fpage></element-citation></ref><ref id="R38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial</article-title><source>Clin Infect Dis</source><year>2021</year><volume>75</volume><fpage>e783</fpage><lpage>e791</lpage></element-citation></ref><ref id="R39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>F</given-names></name><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Piralla</surname><given-names>A</given-names></name><name><surname>Bertoglio</surname><given-names>F</given-names></name><name><surname>de Campos-Mata</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Schubert</surname><given-names>M</given-names></name><name><surname>Cassaniti</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><elocation-id>2670</elocation-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Schedule of sample collection.</title><p>(A) Cross-sectional survey: a total of 1067 participants aged 18 to 59 were enrolled in five counties in Zhejiang, China. The participants had no previous vaccination or were vaccinated with one or two doses of CoronaVac. Venous blood (3−5 ml) was collected on day 0 (Pre-V, no vaccination), day 14 ± 2 (V1-14d), and day 28 ± 3 (V1-28d) after the first dose, and day 30 ± 3 (V2-1m), day 90 ± 7 (V2-3m), day 180 ± 14 (V2-6m), day 270 ± 14 (V2-9m), and day 365 ± 30 (V2-12m) after the second dose. (B) Prospective cohort study: 90 healthy adults aged 18−80 years in Jiaxing city were recruited and administered 4 μg/0.5 mL of CoronaVac following a 3-shot vaccine schedule 28 days and 6 months apart. Following that, venous blood was collected from recipients at five timepoints: day 0 (Pre-V, before vaccination), day 30 ± 3 (V2-1m), day 90 ± 7 (V2-3m), and day 180 ± 14 (V2-6m) after the second dose, and day 30 ± 3 (V3-1m) after the third dose.</p></caption><graphic xlink:href="EMS156671-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Anti-SARS-CoV-2-specific IgG and IgM levels induced by inactivated COVID-19 vaccines.</title><p>(A, B) Dynamic changes in anti-S/anti-N- (A) and anti-RBD- (B) specific IgM/IgG in serum samples from CoronaVac-vaccinated participants at Pre-V, V1-14d, V1-28d, V2-1m, V2-3m, V2-6m, V2-9m, and V2-12m. (C) Correlation between levels of anti-S/anti-N- and anti-RBD-specific antibodies in IgM (left) or IgG (right) at V2-1m. Dates are presented as mean ± SEM. One-way analysis of variance was used for comparison. Correlations were assessed using Pearson’s correlation coefficient. Two-tailed P values were calculated. ns, not significant, * P&lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001.</p></caption><graphic xlink:href="EMS156671-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Neutralizing antibodies induced by inactivated COVID-19 vaccines.</title><p>(A, B) Dynamic changes in GMT of NAb titer (A) and pseudovirus-based inhibition rates of NAbs (B) in serum samples from CoronaVac-vaccinated participants at Pre-V, V2-1m, V2-3m, V2-6m, V2-9m, and V2-12m. (C) Correlation among levels of anti-SARS-CoV-2 IgG, IgM, GMT of NAb titer, and pseudovirus-based inhibition rates of NAbs at V2-1m. One-way analysis of variance was used for comparison. Correlations were assessed using Pearson’s correlation coefficient. Two-tailed P values were calculated. ns, not significant, * P&lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001.</p></caption><graphic xlink:href="EMS156671-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Comparisons of anti-SARS-CoV-2-specific IgG and IgM levels and neutralizing activity before and after booster immunization.</title><p>(A, B) Dynamic changes in anti-S/anti-N IgM/IgG (A), GMT of NAb titer, and pseudovirus-based inhibition rates of NAbs (B) in serum samples from CoronaVac-vaccinated participants at Pre-V, V2-1m, V2-3m, V2-6m, and V3-1m. One-way analysis of variance was used for comparison. Two-tailed P values were calculated. ns, not significant, * P&lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001.</p></caption><graphic xlink:href="EMS156671-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>Neutralizing antibody inhibition rates against Wuhan strain, Delta (B.I.617.2), and Omicron (B.1.1.529) variants for CoronaVac primary- and booster-vaccinated participants, as evaluated by pseudovirus-based neutralization test. The paired Student’s t-test and one-way analysis of variance were used for comparison. Two-tailed P values were calculated. * P&lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001.</p></caption><graphic xlink:href="EMS156671-f005"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline characteristics and IgM and IgG positive rates by timepoint</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left"/><th valign="middle" align="left">Pre-V N=91</th><th valign="middle" align="left">V1-14d N=125</th><th valign="middle" align="left">V1-28d N=91</th><th valign="middle" align="left">V2-1m N=100</th><th valign="middle" align="left">V2-3m N=110</th><th valign="middle" align="left">V2-6m N=160</th><th valign="middle" align="left">V2-9m N=190</th><th valign="middle" align="left">V2-12m N=200</th></tr></thead><tbody><tr><td valign="middle" align="left">Age (years± sd)</td><td valign="middle" align="left">39±9</td><td valign="middle" align="left">40±9</td><td valign="middle" align="left">39±9</td><td valign="middle" align="left">41±11</td><td valign="middle" align="left">42±11</td><td valign="middle" align="left">40±10</td><td valign="middle" align="left">40±10</td><td valign="middle" align="left">41±9</td></tr><tr><td valign="middle" align="left" colspan="9">Sex</td></tr><tr><td valign="middle" align="left">     Male</td><td valign="middle" align="left">37</td><td valign="middle" align="left">45</td><td valign="middle" align="left">37</td><td valign="middle" align="left">49</td><td valign="middle" align="left">54</td><td valign="middle" align="left">80</td><td valign="middle" align="left">85</td><td valign="middle" align="left">75</td></tr><tr><td valign="middle" align="left">     Female</td><td valign="middle" align="left">54</td><td valign="middle" align="left">80</td><td valign="middle" align="left">54</td><td valign="middle" align="left">51</td><td valign="middle" align="left">56</td><td valign="middle" align="left">80</td><td valign="middle" align="left">105</td><td valign="middle" align="left">125</td></tr><tr><td valign="middle" align="left" colspan="9">IgM</td></tr><tr><td valign="middle" align="left">     Concentration (AU/ml)</td><td valign="middle" align="left">0.4±0.02</td><td valign="middle" align="left">5.1±1.0</td><td valign="middle" align="left">5.1±0.9</td><td valign="middle" align="left">1.4±0.2</td><td valign="middle" align="left">0.4±0.1</td><td valign="middle" align="left">0.3±0.04</td><td valign="middle" align="left">0.3±0.04</td><td valign="middle" align="left">0.2±0.03</td></tr><tr><td valign="middle" align="left">     Positive rate (%)</td><td valign="middle" align="left">3.3</td><td valign="middle" align="left">57.6</td><td valign="middle" align="left">75.8</td><td valign="middle" align="left">33.0</td><td valign="middle" align="left">3.6</td><td valign="middle" align="left">4.4</td><td valign="middle" align="left">4.7</td><td valign="middle" align="left">2.0</td></tr><tr><td valign="middle" align="left" colspan="9">IgG</td></tr><tr><td valign="middle" align="left">Concentration (AU/ml)</td><td valign="middle" align="left">0.6±0.1</td><td valign="middle" align="left">3.7±0.5</td><td valign="middle" align="left">64.3±5.8</td><td valign="middle" align="left">79.7±5.7</td><td valign="middle" align="left">29.4±2.4</td><td valign="middle" align="left">10.5±0.9</td><td valign="middle" align="left">8.9±1.0</td><td valign="middle" align="left">6.8±0.9</td></tr><tr><td valign="middle" align="left">Positive rate (%)</td><td valign="middle" align="left">0.0</td><td valign="middle" align="left">7.2</td><td valign="middle" align="left">97.8</td><td valign="middle" align="left">97.0</td><td valign="middle" align="left">88.2</td><td valign="middle" align="left">32.5</td><td valign="middle" align="left">22.1</td><td valign="middle" align="left">13.5</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Baseline characteristics for the prospective cohort</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left"/><th valign="middle" align="center">N=90</th><th valign="middle" align="center">P (%)</th></tr></thead><tbody><tr><td valign="middle" align="left" colspan="3">Age group (years)</td></tr><tr><td valign="middle" align="left">     18-44</td><td valign="middle" align="center">28</td><td valign="middle" align="center">31.1</td></tr><tr><td valign="middle" align="left">     45-64</td><td valign="middle" align="center">21</td><td valign="middle" align="center">23.3</td></tr><tr><td valign="middle" align="left">     65-80</td><td valign="middle" align="center">41</td><td valign="middle" align="center">45.6</td></tr><tr><td valign="middle" align="left" colspan="3">Sex</td></tr><tr><td valign="middle" align="left">     Male</td><td valign="middle" align="center">40</td><td valign="middle" align="center">44.4</td></tr><tr><td valign="middle" align="left">     Female</td><td valign="middle" align="center">50</td><td valign="middle" align="center">55.6</td></tr><tr><td valign="middle" align="left" colspan="3">BMI (kg/m2)</td></tr><tr><td valign="middle" align="left">     &lt; 18.5</td><td valign="middle" align="center">3</td><td valign="middle" align="center">3.3</td></tr><tr><td valign="middle" align="left">     18.5-23.9</td><td valign="middle" align="center">57</td><td valign="middle" align="center">63.4</td></tr><tr><td valign="middle" align="left">     ≥24</td><td valign="middle" align="center">30</td><td valign="middle" align="center">33.3</td></tr><tr><td valign="middle" align="left" colspan="3">Chronic conditions</td></tr><tr><td valign="middle" align="left">     Yes</td><td valign="middle" align="center">30</td><td valign="middle" align="center">33.3</td></tr><tr><td valign="middle" align="left">     No</td><td valign="middle" align="center">60</td><td valign="middle" align="center">66.7</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>GMT results with 95% confidence intervals and positive rate by timepoint and age group</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left">Time point</th><th valign="middle" align="left">Statistic</th><th valign="middle" align="left">Total</th><th valign="middle" align="left">18−44 years</th><th valign="middle" align="left">45−64 years</th><th valign="middle" align="left">≥65 years</th><th valign="middle" align="left">p</th></tr></thead><tbody><tr><td valign="middle" align="left">Pre-V</td><td valign="middle" align="left">GMT</td><td valign="middle" align="left">2.1</td><td valign="middle" align="left">2.2</td><td valign="middle" align="left">2.1</td><td valign="middle" align="left">2.1</td><td valign="middle" align="left">0.908</td></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">95% CI</td><td valign="middle" align="left">2.0−2.2</td><td valign="middle" align="left">1.9-2.4</td><td valign="middle" align="left">1.9-2.4</td><td valign="middle" align="left">2.0-2.3</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">Positive rate (%)</td><td valign="middle" align="left">3.3</td><td valign="middle" align="left">3.6</td><td valign="middle" align="left">4.8</td><td valign="middle" align="left">2.4</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">V2-1m</td><td valign="middle" align="left">GMT</td><td valign="middle" align="left">29.4</td><td valign="middle" align="left">33.2</td><td valign="middle" align="left">36.8</td><td valign="middle" align="left">24.3</td><td valign="middle" align="left">0.019</td></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">95% CI</td><td valign="middle" align="left">23.5−24.2</td><td valign="middle" align="left">25.3-43.4</td><td valign="middle" align="left">24.3-55.7</td><td valign="middle" align="left">20.0-29.5</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">Positive rate (%)</td><td valign="middle" align="left">98.9</td><td valign="middle" align="left">100</td><td valign="middle" align="left">95.2</td><td valign="middle" align="left">100</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">V2-3m</td><td valign="middle" align="left">GMT</td><td valign="middle" align="left">15.5</td><td valign="middle" align="left">22.9</td><td valign="middle" align="left">16.0</td><td valign="middle" align="left">11.5</td><td valign="middle" align="left">&lt;0.01</td></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">95% CI</td><td valign="middle" align="left">13.3−18.0</td><td valign="middle" align="left">17.0-30.9</td><td valign="middle" align="left">12.5-20.5</td><td valign="middle" align="left">9.4-14.2</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">Positive rate (%)</td><td valign="middle" align="left">95.5</td><td valign="middle" align="left">100</td><td valign="middle" align="left">95.2</td><td valign="middle" align="left">92.7</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">V2-6m</td><td valign="middle" align="left">GMT</td><td valign="middle" align="left">6.6</td><td valign="middle" align="left">10.2</td><td valign="middle" align="left">7.9</td><td valign="middle" align="left">4.4</td><td valign="middle" align="left">&lt;0.01</td></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">95% CI</td><td valign="middle" align="left">5.4−8.0</td><td valign="middle" align="left">7.0-14.7</td><td valign="middle" align="left">5.1-12.3</td><td valign="middle" align="left">3.5-5.7</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">Positive rate (%)</td><td valign="middle" align="left">57.8</td><td valign="middle" align="left">82.1</td><td valign="middle" align="left">66.7</td><td valign="middle" align="left">35.6</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left">V3-1m</td><td valign="middle" align="left">GMT</td><td valign="middle" align="left">168.2</td><td valign="middle" align="left">217.2</td><td valign="middle" align="left">152.3</td><td valign="middle" align="left">148.7</td><td valign="middle" align="left">0.369</td></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">95% CI</td><td valign="middle" align="left">139.7−202.6</td><td valign="middle" align="left">165.7-287.7</td><td valign="middle" align="left">97.3-238.5</td><td valign="middle" align="left">110.7-199.7</td><td valign="middle" align="left"/></tr><tr><td valign="middle" align="left"/><td valign="middle" align="left">Positive rate (%)</td><td valign="middle" align="left">100.0</td><td valign="middle" align="left">100</td><td valign="middle" align="left">100</td><td valign="middle" align="left">100</td><td valign="middle" align="left"/></tr></tbody></table></table-wrap></floats-group></article>